Kissei Pharmaceutical Co., Ltd.
Clinical trials sponsored by Kissei Pharmaceutical Co., Ltd., explained in plain language.
Japanese pharmaceutical company developing drugs for urology, diabetes, and rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a daily pill slow the wobble of spinocerebellar degeneration? Results expected Mar 2027 (estimated)
-
Can a daily pill slow the wobble of spinocerebellar degeneration?
Disease control OngoingThis Phase 3 trial tests whether an experimental oral drug, KPS-0373, can improve movement and coordination in people with spinocerebellar degeneration, a condition that causes progressive clumsiness and balance problems. About 142 Japanese adults with mild to moderate ataxia wil…
Phase 3 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill could ease endometriosis pain without needles
Symptom relief OngoingThis Phase 3 trial tests an oral drug called KLH-2109 for pelvic pain in 288 women with endometriosis. Participants receive either KLH-2109 or a standard injection (leuprorelin acetate) for 12 weeks. The goal is to see if the new pill works as well as the injection in reducing da…
Phase 3 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC